Current management of parainfuenza pneumonitis in immunocompromised patients: A review

Infection and Drug Resistance

Volumn 5, Issue 1, 2012, Pages 121-127

  Falsey, Ann R ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Antiviral agents; Immunocompromised host; Parainfuenza virus

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; BCX 2798; BCX 2855; DAS 181; DIHYDROHEPTAPRENOL; GAMMA INTERFERON; GLYCOPROTEIN GP 41; IMIQUIMOD; IMMUNOGLOBULIN; PROTEIN C; RIBAVIRIN; SIALIDASE; STEROID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; DRUG BINDING; DRUG EFFICACY; DRUG SCREENING; HOST RESISTANCE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; REVIEW; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; VIRUS PNEUMONIA; VIRUS SHEDDING;

EID: 84872945705     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/idr.s25874     Document Type: Review

References (49)

1. Henrickson KJ. Parainfuenza viruses. Clin Microbiol Rev. 2003;16(2): 242-264.
2. Hall CB. Respiratory syncytial virus and parainfuenza virus. N Engl J Med. 2001;344(25):1917-1928.
3. Rihkanen H, Ronkko E, Nieminen T, et al. Respiratory viruses in laryngeal croup of young children. J Pediatr. 2008;152(5):661-665.
4. Stankova J, Carret AS, Moore D, et al. Long-term therapy with aero- solized ribavirin for parainfuenza 3 virus respiratory tract infection in an infant with severe combined immunodefciency. Pediatr Transplant. 2007;11(2):209-213.
5. Moss RB, Steigbigel RT, Sanders RL, Fang F. Perspective: emerging challenges in the treatment of infuenza and parainfuenza in transplant patients. Adv Virol. 2011;2011:910-930. Epub July 7, 2011.
6. Boeckh M. The challenge of respiratory virus infections in hematopoi- etic cell transplant recipients. Br J Haematol. 2008;143(4):455-467.
7. Moscona A. Entry of parainfuenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest. 2005;115(7): 1688-1698.
8. Nishino R, Ikeda K, Hayakawa T, Takahashi T, Suzuki T, Sato M. Syntheses of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid ana- logues modifed by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfuenza virus type 1. Bioorg Med Chem. 2011;19(7):2418-2427.
9. Mao H, Thakur CS, Chattopadhyay S, Silverman RH, Gudkov A, Banerjee AK. Inhibition of human parainfuenza virus type 3 infection by novel small molecules. Antiviral Res. 2008;77(2):83-94.
10. Spriggs MK, Murphy BR, Prince GA, Olmsted RA, Collins PL. Expression of the F and HN glycoproteins of human parainfuenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol. 1987;61(11):3416-3423.
11. Henderson F W. Pulmonary cell-mediated cytotoxicity in hamsters with parainfluenza virus type 3 pneumonia. Am Rev Respir Dis. 1979;120(1):41-47.
12. Hou S, Doherty PC, Zijlstra M, Jaenisch R, Katz JM. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells. J Immunol. 1992;149(4):1319-1325.
13. Dave V P, Allan JE, Slobod KS, et al. Viral cross-reactivity and antigenic determinants recognized by human parainfuenza virus type 1-specifc cytotoxic T-cells. Virolog y. 1994;199(2):376-383.
14. Karp D, Willis J, Wilfert CM. Parainfuenza virus II and the immuno- compromised host. Am J Dis Child. 1974;127(4):592-593.
15. Delage G, Brochu P, Pelletier M, Jasmin G, Lapointe N. Giant-cell pneumonia caused by parainfuenza virus. J Pediatr. 1979;94(3): 426-429.
16. Marcolini JA, Malik S, Suki D, Whimbey E, Bodey G P. Respiratory disease due to parainfuenza virus in adult leukemia patients. Eur J Clin Microbiol Infect Dis. 2003;22(2):79-84.
17. Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfuenza virus in adult bone marrow transplant recipients. Clin Infect Dis. 1996;23(5):1033-1037.
18. Wendt CH, Hertz MI. Respiratory syncytial virus and parainfuenza virus infections in the immunocompromised host. Semin Respir Infect. 1995;10(4):224-231.
19. Whimbey E, Champlin RE, Couch RB, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis. 1996;22(5):778-782.
20. Vilchez RA, McCurry K, Dauber J, et al. The epidemiology of parain- fuenza virus infection in lung transplant recipients. Clin Infect Dis. 2001;33(12):2004-2008.
21. Lujan-Zilbermann J, Benaim E, Tong X, Srivastava DK, Patrick CC, DeVincenzo J P. Respiratory virus infections in pediatric hematopoietic stem cell transplantation. Clin Infect Dis. 2001;33(7):962-968.
22. Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfuenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7 Suppl:11S-15S.
23. Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infec- tions in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol. 2002;119(4):1125-1132.
24. DeFabritus AM, Riggio RR, David DS, Senterft LB, Cheigh JS, Stenzel KH. Parainfuenza type 3 in a transplant unit. JAMA. 1979;241(4): 384-386.
25. Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2001;28(8):759-763.
26. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K. Parainfuenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diag- nosis and ribavirin treatment. Clin Infect Dis. 2001;32(3):413-418.
27. Wendt CH, Weisdorf DJ, Jordan MC, Balfour HH Jr, Hertz MI. Parainfluenza virus respiratory infection after bone marrow transplantation. N Engl J Med. 1992;326(14):921-926.
28. Dignan F, Alvares C, Riley U, et al. Parainfuenza type 3 infection post stem cell transplant: high prevalence but low mortality. J Hosp Infect. 2006;63(4):452-458.
29. Peck AJ, Englund JA, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptom- atic parainfuenza virus infection. Blood. 2007;110(5):1681-1688.
30. Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K. A parainfuenza-3 outbreak in a SCT unit: sepsis with multi-organ fail- ure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant. 2011;46(12):1545-1550.
31. Frank JA Jr, Warren RW, Tucker JA, Zeller J, Wilfert CM. Disseminated parainfuenza infection in a child with severe combined immunodefciency. Am J Dis Child. 1983;137(12):1172-1174.
32. Lange T, Franke G, Niederwieser D. Parotitis associated with a parain- fuenza virus type 3 infection during aplasia after unrelated allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47(8):1714-1715.
33. Erard V, Chien J W, Kim H W, et al. Airfow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193(12):1619-1625.
34. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med. 1983;308(24):1443-1447.
35. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19(9):905-908.
36. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW. Parainfluenza virus type 3 infections in hematopoetic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis. 2000;31(6):1516-1518.
37. Wright JJ, O'Driscoll G. Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavi- rin and methylprednisolone. J Heart Lung Transplant. 2005;24(3): 343-346.
38. McIntosh K, Kurachek SC, Cairns LM, Burns JC, Goodspeed B. Treatment of respiratory viral infection in an immunodefcient infant with ribavirin aerosol. Am J Dis Child. 1984;138(3):305-308.
39. Mao H, Chattopadhyay S, Banerjee AK. N-terminally truncated C protein, CNDelta25, of human parainfuenza virus type 3 is a potent inhibitor of viral replication. Virology. 2009;394(1):143-148.
40. Chen YB, Driscoll J P, McAfee SL, et al. Treatment of parainfuenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation. Clin Infect Dis. 2011;53(7):e77-e80.
41. Triana-Baltzer GB, Sanders RL, Hedlund M, et al. Phenotypic and genotypic characterization of infuenza virus mutants selected with the sialidase fusion protein DAS181. J Antimicrob Chemother. 2011;66(1):15-28.
42. Watanabe M, Mishin V P, Brown SA, et al. Effect of hemagglutinin- neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfuenza type 3 chimera virus in mice. Antimicrob Agents Chemother. 2009;53(9):3942-3951.
43. Alymova I V, Watanabe M, Boyd KL, Chand P, Babu YS, Portner A. Effcacy of the novel parainfuenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice-further evaluation. Antivir Ther. 2009;14(7):891-898.
44. Pastey MK, Gower TL, Spearman PW, Crowe JE Jr, Graham BS. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfuenza virus type 3. Nat Med. 2000;6(1):35-40.
45. Lambert DM, Barney S, Lambert AL, et al. Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A. 1996;93(5):2186-2191.
46. Zhao H, De B P, Das T, Banerjee AK. Inhibition of human parain- fuenza virus-3 replication by interferon and human MxA. Virology. 1996;220(2):330-338.
47. Ottolini MG, Hemming VG, Piazza FM, Johnson SA, Darnell ME, Prince GA. Topical immunoglobulin is an effective therapy for parainfu- enza type 3 in a cotton rat model. J Infect Dis. 1995;172(1):243-245.
48. Ottolini MG, Porter DD, Blanco JC, Prince GA. A cotton rat model of human parainfuenza 3 laryngotracheitis: virus growth, pathology, and therapy. J Infect Dis. 2002;186(12):1713-1717.
49. Prince GA, Porter DD. Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia in a cotton rat model using topical antibody and glucocorticosteroid. J Infect Dis. 1996;173(3):598-608.